Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

93.58EUR
25 Jun 2019
Change (% chg)

-- (--)
Prev Close
€93.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
551,912
52-wk High
€102.90
52-wk Low
€81.42

Latest Key Developments (Source: Significant Developments)

Merck KGaA Affirms Versum Deal Expected To Close In Second Half
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Merck KGaA ::PLEASED THAT VERSUM STOCKHOLDERS HAVE VOTED IN FAVOR OF US MOVING FORWARD WITH THIS TRANSACTION.TRANSACTION IS EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.  Full Article

Versum Materials Stockholders Approve Merger With Merck KGaA
Monday, 17 Jun 2019 

June 17 (Reuters) - Versum Materials Inc::VERSUM MATERIALS STOCKHOLDERS APPROVE MERGER WITH MERCK KGAA, DARMSTADT, GERMANY.VERSUM MATERIALS INC - VERSUM CONTINUES TO EXPECT TRANSACTION WITH MERCK KGAA TO CLOSE IN SECOND HALF OF 2019.  Full Article

Bioxcel Therapeutics Announces FDA Clearance Of IND Application
Monday, 3 Jun 2019 

June 3 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR TRIPLE COMBINATION IN PANCREATIC CANCER AND CTA ACCEPTANCE FOR DOUBLE COMBINATION IN AGGRESSIVE FORM OF PROSTATE CANCER (TNEPC) FOR LEAD IMMUNO-ONCOLOGY PROGRAM, BXCL701.BIOXCEL THERAPEUTICS INC - MHRA ACCEPTS CLINICAL APPLICATION FOR DOUBLE COMBINATION TRIAL OF BXCL701 AND KEYTRUDA IN TNEPC PATIENTS.BIOXCEL - COLLABORATING WITH NEKTAR THERAPEUTICS, MERCK KGAA, PFIZER TO CONDUCT TRIAL TO EVALUATE TRIPLE COMBINATION OF BXCL701, BEMPEGALDESLEUKIN & AVELUMAB.  Full Article

Merck KGaA CFO Says No Concrete Plans At The Moment To Divest Any Businesses
Friday, 12 Apr 2019 

April 12 (Reuters) - Merck Kgaa analyst call::CFO SAYS NO SIZABLE TAKEOVER TRANSACTIONS PLANNED IN THE FORESEEABLE FUTURE AFTER VERSUM DEAL, DELEVERAGING IS FOCUS OVER NEXT COUPLE OF YEARS.CFO SAYS WANT TO KEEP A DIVERSIFIED 3 PILLAR STRUCTURE FOR THE COMPANY.CFO SAYS THERE ARE NO CONCRETE PLANS AT THE MOMENT TO DIVEST ANY BUSINESSES IN THE NEAR FUTURE.  Full Article

FDA Approves New Oral Treatment For Multiple Sclerosis
Friday, 29 Mar 2019 

March 29 (Reuters) - Merck KGaA ::FDA APPROVES NEW ORAL TREATMENT FOR MULTIPLE SCLEROSIS.FDA - APPROVED MAVENCLAD TABLETS TO TREAT RELAPSING FORMS OF MS IN ADULTS, TO INCLUDE RELAPSING-REMITTING DISEASE & ACTIVE SECONDARY PROGRESSIVE DISEASE.FDA - GRANTED APPROVAL OF MAVENCLAD TO EMD SERONO INC.FDA - MAVENCLAD HAS A BOXED WARNING FOR AN INCREASED RISK OF MALIGNANCY AND FETAL HARM.FDA - MAVENCLAD IS NOT RECOMMENDED FOR MS PATIENTS WITH CLINICALLY ISOLATED SYNDROME.  Full Article

Entegris Says Believes Combination Of Entegris & Versum To Be In Best Interests Of Stockholders Of Each Co
Friday, 29 Mar 2019 

March 29 (Reuters) - Entegris Inc ::ENTEGRIS COMMENTS ON VERSUM MATERIALS ANNOUNCEMENT.ENTEGRIS INC - BELIEVES COMBINATION OF ENTEGRIS AND VERSUM TO BE IN BEST INTERESTS OF STOCKHOLDERS OF EACH COMPANY.ENTEGRIS INC - BOARDS OF ENTEGRIS AND VERSUM MATERIALS CONTINUE TO RECOMMEND PREVIOUSLY ANNOUNCED MERGER.  Full Article

Versum Materials' Board Of Directors Rejects Unsolicited Tender Offer From Merck KGaA
Friday, 29 Mar 2019 

March 29 (Reuters) - Versum Materials Inc ::VERSUM MATERIALS’ BOARD OF DIRECTORS REJECTS UNSOLICITED TENDER OFFER FROM MERCK KGAA.VERSUM MATERIALS INC - DETERMINES TO ENGAGE IN DISCUSSIONS WITH MERCK.VERSUM MATERIALS INC - MEETING OCCURRED BETWEEN REPRESENTATIVES OF VERSUM AND MERCK PURSUANT TO A LIMITED WAIVER GRANTED BY ENTEGRIS.VERSUM MATERIALS- AFTER CONSIDERATION, CONSULTATION WITH FINANCIAL, LEGAL ADVISORS, BOARD DETERMINED TO REJECT UNSOLICITED TENDER OFFER FROM MERCK KGAA.VERSUM MATERIALS - DETERMINED MERCK'S PROPOSAL COULD REASONABLY BE EXPECTED TO RESULT IN SUPERIOR PROPOSAL UNDER MERGER AGREEMENT WITH ENTEGRIS.VERSUM MATERIALS INC - BOARD HAS NOT CHANGED ITS RECOMMENDATION IN SUPPORT OF PENDING ALL-STOCK MERGER OF EQUALS WITH ENTEGRIS.VERSUM MATERIALS - BOARD AUTHORIZED MANAGEMENT AND ITS ADVISERS TO ENGAGE IN FURTHER DISCUSSIONS WITH, AND PROVIDE NON-PUBLIC INFORMATION TO, MERCK.  Full Article

Merck And GenScript To Cooperate To Accelerate Industrial Production Of Cell And Gene Therapies In China
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Merck KGaA ::MERCK AND GENSCRIPT INTEND TO COOPERATE TO ACCELERATE THE INDUSTRIAL PRODUCTION OF CELL AND GENE THERAPIES IN CHINA.SIGNING OF A NON-BINDING MEMORANDUM OF UNDERSTANDING.COLLABORATION TO BUILD GLOBAL-STANDARD PLATFORM FOR PLASMID AND VIRUS MANUFACTURING IN CHINA.MERCK PLANS TO PROVIDE COMPREHENSIVE PRODUCTS, SERVICES AND TRAINING TO GENSCRIPT ON MANUFACTURING.  Full Article

Merck Announces Collaboration With Iktos For Generative AI Technology
Thursday, 14 Mar 2019 

March 14 (Reuters) - MERCK KGAA ::ANNOUNCES COLLABORATION WITH IKTOS FOR GENERATIVE ARTIFICIAL INTELLIGENCE (AI) TECHNOLOGY.COLLABORATION AGREEMENT ENABLES MERCK KGAA, DARMSTADT, GERMANY, ACCESS TO IKTOS AI TECHNOLOGY ACROSS THREE DRUG DISCOVERY PROJECTS.  Full Article

BioXcel Therapeutics Announces Addition Of Merck KGaA, Darmstadt, Germany, And Pfizer To Clinical Collaboration With Nektar
Monday, 4 Mar 2019 

March 4 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES ADDITION OF MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER TO CLINICAL COLLABORATION WITH NEKTAR FOR DEVELOPMENT OF TRIPLE-COMBINATION THERAPY IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - BTI WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.BIOXCEL THERAPEUTICS INC - MERCK KGAA, DARMSTADT, GERMANY AND PFIZER SUPPLYING AVELUMAB AND NEKTAR SUPPLYING NKTR-214..BIOXCEL THERAPEUTICS INC - BTI AND NEKTAR WILL EQUALLY SHARE ALL DEVELOPMENT COSTS.  Full Article

German stocks - Factors to watch on June 14

BERLIN/FRANKFURT, June 14 The following are some of the factors that may move German stocks on Friday: